162 related articles for article (PubMed ID: 33087019)
21. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
22. JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I.
Berman JN; Greer WL; Archambeault S; Loh ML; Riddell C; Morash B; Dumas N; Fernandez CV; Ludman MD
Pediatr Blood Cancer; 2008 Nov; 51(5):689-91. PubMed ID: 18623221
[TBL] [Abstract][Full Text] [Related]
23. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
24. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
25. Polycythaemia vera and JAK2 mutation.
Mannucci PM
Intern Emerg Med; 2007 Jun; 2(2):147. PubMed ID: 17634823
[No Abstract] [Full Text] [Related]
26. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
27. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
28. [Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].
Araki N; Takimoto R; Chiba H; Araki H; Sato T; Iyama S; Hirakawa M; Ono K; Kawano Y; Takada K; Miyanishi K; Kobune M; Matsunaga T; Kato J; Nakamura T; Niitsu Y
Rinsho Ketsueki; 2007 Jul; 48(7):554-8. PubMed ID: 17695304
[TBL] [Abstract][Full Text] [Related]
29. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
30. A Case of Recurrent Ischemic Stroke Involving Subacute, Progressive Intracranial Cerebral Arterial Sclerosis Prior to Diagnosis with JAK2-mutated Polycythemia Vera.
Nezu T; Aoki S; Ochi K; Sugihara S; Takahashi T; Hosomi N; Maruyama H; Matsumoto M
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):e4-6. PubMed ID: 26432562
[TBL] [Abstract][Full Text] [Related]
31. JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.
Inami T; Okabe M; Matsushita M; Kobayashi N; Inokuchi K; Hata N; Seino Y; Shimizu W
Heart Vessels; 2016 Oct; 31(10):1714-6. PubMed ID: 26825737
[TBL] [Abstract][Full Text] [Related]
32. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
33. Vertebral artery thrombosis: a rare presentation of primary polycythaemia.
Gul HL; Lau SY; Chan-Lam D; Ng JP
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24862411
[TBL] [Abstract][Full Text] [Related]
34. The role of parathyroidectomy in JAK2 mutation negative polycythemia vera.
Kulaylat AN; Jung EE; Saunders BD
Int J Hematol; 2014 Dec; 100(6):615-8. PubMed ID: 25209606
[TBL] [Abstract][Full Text] [Related]
35. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
36. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; FoĆ R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
37. Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.
Wen H; Jin D; Chen Y; Cui B; Xiao T
BMC Neurol; 2021 Jun; 21(1):225. PubMed ID: 34134639
[TBL] [Abstract][Full Text] [Related]
38. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
39. High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance.
Park CH; Lee KO; Jang JH; Jung CW; Kim JW; Kim SH; Kim HJ
J Clin Pathol; 2016 Aug; 69(8):737-41. PubMed ID: 27198504
[TBL] [Abstract][Full Text] [Related]
40. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]